Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 8Prostatic Neoplasms 5Polycystic Ovary Syndrome 5Multiple Myeloma 5Colorectal Neoplasms 5Small Cell Lung Carcinoma 4Rectal Neoplasms 3Neoplasms 3Neoplasm Metastasis 3Stomach Neoplasms 2Pancreatic Neoplasms 2Fibrosis 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Intraductal, Noninfiltrating 2Carcinoma, Hepatocellular 2Breast Carcinoma In Situ 2Wilms Tumor 1Waldenstrom Macroglobulinemia 1Venous Thromboembolism 1Urinary Bladder Neoplasms 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Thrombosis 1Sprains and Strains 1Smoldering Multiple Myeloma 1Sepsis 1Sarcoma, Ewing 1Sarcoma, Clear Cell 1Sarcoma 1

Interventions

Oxaliplatin 290Capecitabine 206Fluorouracil 181Cisplatin 168Docetaxel 138S 1 (combination) 132Paclitaxel 121Leucovorin 116Irinotecan 106pembrolizumab 103Trastuzumab 71apatinib 56Nivolumab 56sintilimab 45Drug Therapy 43Surgical Procedures, Operative 37Radiotherapy 37Bevacizumab 37Ramucirumab 34titanium silicide 31Hyperthermic Intraperitoneal Chemotherapy 30Epirubicin 30Carboplatin 30tislelizumab 28Cyclophosphamide 27XELOX 24Tegafur 23Folfox protocol 22Albumin-Bound Paclitaxel 22camrelizumab 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Stomach Neoplasms × Simvastatin × Clear all
NCT03086291 2019-12-30

A Phase I Study of High Dose Simvastatin in Patients With Gastrointestinal Tract Cancer Who Failed to Standard Chemotherapy

Samsung Medical Center

Phase 1 Unknown
9 enrolled
Gastrointestinal

Stomach Neoplasms

NCT01099085 2017-02-17

Trial of XP (Capecitabine/CDDP) Simvastatin in Advanced Gastric Cancer Patients

Samsung Medical Center

Phase 3 Completed
207 enrolled
Gastrointestinal

Neoplasm Metastasis, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡